ARCHIVES

Deals and Collaborations: Firms Get First Payment From Bristol-Myers for Taxol

This article is from The Cancer Letter archive.

Vol. 25 No. 09 | March 5, 1999

Download PDF Visit The Full Archive

Related Articles

Reimbursement Policy By Philadelphia Blue Cross Further Explained

April 21, 1989

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

October 26, 2012

New Reagan Budget Or FY 1982 gives NCI $1.026 Billion

March 6, 1981

NTP Committee Finds Five Test Reports Show “Limited” Evidence Of Carcinogenicity

February 27, 1981

NCCS Networker Volume 2 Issue 2, Spring 1988

April 13, 1988

Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease

June 29, 2012